Abstract:Objective:To explore the genetic mutation, clinical characteristics, diagnosis and treatment of patients with hereditary coagulation factor FⅪ deficiency.Methods:On August 10 and October 30, 2020, two patients with hereditary FⅪ deficiency who were admitted at Department of Hematology, West China Hospital of Sichuan University were selected as research subjects. Patients 1 and 2 were numbered according to visiting time. Diagnosis was made according to coagulation function test and results of gene sequencing F11 gene.Clinical observation or symptomatic treatment were performed according to clinical bleeding symptom and severity. Novel mutations were confirmed by retrieving Human Gene Mutation database (HGMD), Single Nucleotide Polymorphism Database (dbSNP) and PubMed database. Pathogenicity of the novel missense mutation was predicted by computational software of Mutation Taster, Polyphen-2, and PROVEAN. Follow-up of patients was conducted until February 28, 2021. Clinical manifestations and process of diagnosis and treatment of two patients were analyzed retrospectively. China National Knowledge Infrastructure database, Wanfang Data Knowledge Service Platform, PubMed database were searched for the same and similar case reports as F11 genetic mutation in this study.Retrieval time was from database inception to February 28, 2021. Types of genetic mutations and clinical manifestations related to patients in this study were summarized.This study meeted the requirements of the World Medical Association Declaration of Helsinki revised in 2013. Informed consent of patients was obtained from pateints. Results:① Results of medical history: patient 1, a 24 years old man, was admitted due to " hematoma after soft tissue trauma in left thigh and preoperative examination revealed coagulation dysfunction" and did not complain of significant discomfort.Patient 2, a 32 years old woman, was admitted due to " pre-pregnancy physical examination found prolonged activated partial thromboplastin time (APTT)" and complained of occasional ecchymosis.② Results of related laboratory examination: APTT, prothrombin time (PT) and FⅪ activity (FⅪ∶C) of patient 1 were 97.9 s, 11.9 s and 0.6%, while patient 2 were 95.4 s, 12.5 s, and 1.2%, respectively. ③ Results of DNA sequencing: patient 1 had a compound heterozygous missense mutation of F11 gene at c. 149G>T(p.Cys50Phe) and c. 1204C>T (p.Gln402Ter), while patient 2 had a homozygous deletion of F11 gene at c. 1058delA (p.Asn353ThrfsTer18). ④ F11 gene missense mutation at c. 149G>T(p.Cys50Phe) and deletion c. 1058delA(p.Asn353ThrfsTer18) were two novel mutations and both were pathogenic.⑤Results of treatment and follow-up: two patients received clinical observation. At end of follow-up, general condition of the patients was good. ⑥ Results of literatures review: among 10 patients reported in 6 relevant literatures, there were 1, 3, 6 patients caused by heterozygous nonsense mutation of c. 1204C>T(p.Gln402Ter), nonsense mutation of c. 1202C>T(p.Trp401Ter) adjacent to c. 1204C>T (p.Gln402Ter) and missense mutations near the position of c. 149G>T(p.Cys50Phe), respectively. Conclusions:Two novel mutations of hereditary FⅪ deficiency namely a missense mutation at c. 149G>T(p.Cys50Phe) and a deletion at c. 1058delA(p.Asn353ThrfsTer18) of F11 gene were reported in this study. Both of the two mutations related to decrease of FⅪ∶C.

Correlation of gene polymorphisms of coagulation factor Ⅶ with its activity and coagulopathy in patients with traumatic brain injury

Coagulopathy in Traumatic Brain Injury and Its Correlation with Progressive Hemorrhagic Injury: A Systematic Review and Meta-Analysis

Change in Plasma Microparticle Procoagulant Activity after Traumatic Brain Injury

Contribution of Factor VII Polymorphisms to Coagulopathy in Patients with Isolated Traumatic Brain Injury.

Dynamically Monitoring Tissue Factor and Tissue Factor Pathway Inhibitor Following Secondary Brain Injury

Polymorphisms in the Genes for Coagulation Factor II, V, VII in Patients Undergoing Coronary Angiography

Validating the Incidence of Coagulopathy and Disseminated Intravascular Coagulation in Patients with Traumatic Brain Injury – Analysis of 242 Cases

[Association of Coagulation Factor V, VII Gene Polymorphisms with Coronary Heart Disease].

Relationship Between Plasma Coagulation Factor Ⅶ and Progressive Hemorrhagic Injury in Patients with Isolated Traumatic Brain Injury

Genetic analysis of patients with hereditary coagulation factor Ⅺ deficiency and literatures review

Role of small-dose recombinant human coagulation factor Ⅶ a for coagulopathy in patients with isolated traumatic brain injury

Coagulation changes after severe head traumas

Promoter Methylation of Coagulation Factor Ⅶ in Patients with Traumatic Brain Injury and Its Association with Intracranial Progressive Hemorrhagic Injury

The influence of hemocoagulation disorders on the development of posttraumatic cerebral infarction and outcome in patients with moderate or severe head trauma.

Computed Tomographic Parameters Correlate with Coagulation Disorders in Isolated Traumatic Brain Injury

Activity of Factor VII in Patients with Isolated Blunt Traumatic Brain Injury: Association with Coagulopathy and Progressive Hemorrhagic Injury.

Relationship between admission coagulopathy and prognosis in children with traumatic brain injury: a retrospective study

Activity of factor VII in patients with isolated blunt traumatic brain injury

Factors Associated with the Development of Coagulopathy after Open Traumatic Brain Injury

Correlation Between Coagulation-Fibrinolysis and Progressive Intracranial Hemorrhage and Prognosis in Patients with Acute Traumatic Brain Injury

Critical traumatic brain injury is associated with worse coagulopathy